Active use of a sunscreen and quality of life in melanoma patients (feasibility study)

Active use of a sunscreen and quality of life in melanoma patients (feasibility study) - LSF50-Mel-QoL

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00014331

Enrollment

Registered

2018-03-23

Start date

2018-04-04

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C43.9

Interventions

Group 1: Information about sun protection measures according to the S3 guideline of the dermatological society, with autonomous free choice of sun protection plus active administration of a sun protec

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Stage I and II melanoma patients with histologically confirmed, cutaneous primary malignant melanoma, i.e. no metastases or lymph node manifestation, no adjuvant interferon or other therapy. Patients with new disease (after surgery) and patients after surgery in the 1st + 2nd year of follow-up examinations. Prerequisites are the ability to fill out a German questionnaire and the willingness to undergo a questionnaire survey. Age between 18 and 75 years

Exclusion criteria

Exclusion criteria: Mucosal melanomas and ocular melanomas, the presence of satellite, lymph node or distant metastases (clinically or apparative diagnosis)

Design outcomes

Primary

Measure	Time frame
Patient data relevant to care is recorded using standardized questionnaires (DLQI/Dermatology Life Quality Index, EQ5D-5L/five-level version of the EuroQol five-dimensional questionnaire and HADS/Hospital Anxiety and Depression Scale) and a patient diary. Patients are interviewed twice: at the beginning of the study and after 3 months as part of aftercare, in accordance with the guidelines of the German Dermatological Society. Primary endpoint: Is there any evidence of a change in quality of life compared to the two groups (study arms).	—

Measure

Time frame

Patient data relevant to care is recorded using standardized questionnaires (DLQI/Dermatology Life Quality Index, EQ5D-5L/five-level version of the EuroQol five-dimensional questionnaire and HADS/Hospital Anxiety and Depression Scale) and a patient diary. Patients are interviewed twice: at the beginning of the study and after 3 months as part of aftercare, in accordance with the guidelines of the German Dermatological Society. Primary endpoint: Is there any evidence of a change in quality of life compared to the two groups (study arms).

—

Secondary

Measure	Time frame
Are there any indications of a change in the quality of life in the before/after comparison?	—

Countries

Germany

Contacts

Public ContactTim Maisch

Universitätsklinikum Regensburg Klinik & Poliklinik für Dermatologie

tim.maisch@klinik.uni-regensburg.de09419449532

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026